Alcaftadine 0.25% Versus Olopatadine 0.2% In Prevention Of Ocular Itching In Allergic Conjunctivitis

被引：2
|
作者：
McLaurin, Eugene B. [1 ]
Marsico, Nicholas P. [2 ]
Ciolino, Joseph B. [3 ]
Villanueva, Linda [4 ]
Williams, Julia M. [4 ]
Hollander, David A. [4 ]
机构：
[1] Total Eye Care PA, Memphis, TN USA
[2] East West Eye Inst, Los Angeles, CA USA
[3] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.986
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
961
引用
收藏
页码：AB278 / AB278
页数：1
相关论文
共 50 条
  • [41] Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort
    Michael Ganz
    Elizabeth Koll
    Jean Gausche
    Paul Detjen
    Nicholas Orfan
    Advances in Therapy, 2003, 20 : 79 - 91
  • [42] Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort
    Ganz, M
    Koll, E
    Gausche, J
    Detjen, P
    Orfan, N
    ADVANCES IN THERAPY, 2003, 20 (02) : 79 - 91
  • [43] Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis
    Meier, Edward J.
    Torkildsen, Gail L.
    Gow, James A.
    McNamara, Timothy R.
    Gomes, Paul J.
    Williams, Jon I.
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (03) : 265 - 274
  • [44] Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial
    Bill Cavanagh
    Paul J. Gomes
    Christopher E. Starr
    Kelly K. Nichols
    Todd C. Brady
    Ophthalmology and Therapy, 2022, 11 : 1449 - 1461
  • [45] Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial
    Cavanagh, Bill
    Gomes, Paul J.
    Starr, Christopher E.
    Nichols, Kelly K.
    Brady, Todd C.
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (04) : 1449 - 1461
  • [46] Pemirolast potassium, a novel mast-cell stabilizer prevents ocular itching in allergic conjunctivitis patients.
    Amdahl, LD
    Graves, AL
    Rosner, B
    Abelson, MB
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S926 - S926
  • [47] Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis:: An open-label study
    Dogru, M
    Özmen, A
    Ertürk, H
    Sanli, Ö
    Karatas, A
    CLINICAL THERAPEUTICS, 2002, 24 (08) : 1309 - 1321
  • [48] Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge
    Mah, Francis S.
    Rosenwasser, Lanny J.
    Townsend, William D.
    Greiner, Jack V.
    Bensch, George
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1445 - 1452
  • [49] Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge
    Abelson, Mark B.
    Spangler, Dennis L.
    Epstein, Arthur B.
    Mah, Francis S.
    Crampton, H. Jerome
    CURRENT EYE RESEARCH, 2007, 32 (12) : 1017 - 1022
  • [50] Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
    Epstein, Arthur B.
    Van Hoven, Peter T.
    Kaufman, Alan
    Carr, Warner W.
    CLINICAL OPHTHALMOLOGY, 2009, 3 : 329 - 336
12345